All In Biotech

Drug Trial Radar · NCT03690986

VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Integrated Pilot Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer

Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

35

Actual

Start

Nov 1, 2018

Primary completion

Apr 9, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
Emory UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Vaccinex Inc.
First posted
Oct 1, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies how well anti-semaphorin 4D (SEMA4D) monoclonal antibody VX15/2503 (VX15/2503) with or without ipilimumab and/or nivolumab work in treating patients with stage I-IVA head and neck squamous cell cancer. Monoclonal antibodies, such as VX15/2503, ipilimumab, and nivolumab, may interfere with the ability of tumor cells to grow and spread.

Conditions

  • Squamous Cell Carcinoma of the Head and Neck

Interventions

  • VX15/2503Biological

    Given IV

  • IpilimumabBiological

    Given IV

  • NivolumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in immune profile in the tumor microenvironmentTime frame: Baseline up to 4-8 weeks after surgery
  2. Change in circulating percentage of immune suppressor subsets in peripheral bloodTime frame: Baseline up to 4-8 weeks after surgery
  3. Phenotypic shifts in T lymphocyte subsets in peripheral bloodTime frame: Baseline up to 4-8 weeks after surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Emory University Hospital Midtown

    Atlanta, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.